WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 522362
CAS#: 1252679-52-9 (HCl)
Description: ITX-5061 is a Hepatitis C Virus Entry Inhibitor or a scavenger receptor B1 antagonist. ITX 5061 has entered phase 1 clinical trials in hepatitis C virus (HCV)-infected humans. ITX-5061 possesses a unique mechanism of action that prevents the hepatitis C virus from entering liver cells and has demonstrated potent preclinical antiviral activity against all HCV genotypes. Preclinical studies have shown ITX-5061 to be a potent and selective inhibitor of HCV entry into hepatocytes, capable of preventing virus binding/fusion and cell to cell spread, suggesting ITX-5061 may reduce re-infection rates following liver transplant.
MedKoo Cat#: 522362
Name: ITX-5061 HCl
CAS#: 1252679-52-9 (HCl)
Chemical Formula: C30H38ClN3O7S
Exact Mass:
Molecular Weight: 620.21
Elemental Analysis: C, 58.10; H, 6.18; Cl, 5.72; N, 6.78; O, 18.06; S, 5.17
ITX-5061 HCl is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.
Related CAS #: 1252679-52-9 (HCl) 848144-15-0 (free base)
Synonym: ITX-5061; ITX 5061; ITX5061.
IUPAC/Chemical Name: N-(5-(tert-butyl)-2-methoxy-3-(methylsulfonamido)phenyl)-2-(4-(2-morpholinoethoxy)naphthalen-1-yl)-2-oxoacetamide hydrochloride
InChi Key: ICIJBYYMEBOTQP-UHFFFAOYSA-N
InChi Code: InChI=1S/C30H37N3O7S.ClH/c1-30(2,3)20-18-24(28(38-4)25(19-20)32-41(5,36)37)31-29(35)27(34)23-10-11-26(22-9-7-6-8-21(22)23)40-17-14-33-12-15-39-16-13-33;/h6-11,18-19,32H,12-17H2,1-5H3,(H,31,35);1H
SMILES Code: O=C(NC1=CC(C(C)(C)C)=CC(NS(=O)(C)=O)=C1OC)C(C2=C3C=CC=CC3=C(OCCN4CCOCC4)C=C2)=O.[H]Cl
The following data is based on the product molecular weight 620.21 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Zhu YZ, Qian XJ, Zhao P, Qi ZT. How hepatitis C virus invades hepatocytes: the mystery of viral entry. World J Gastroenterol. 2014 Apr 7;20(13):3457-67. doi: 10.3748/wjg.v20.i13.3457. Review. PubMed PMID: 24707128; PubMed Central PMCID: PMC3974512.
2: Sulkowski MS, Kang M, Matining R, Wyles D, Johnson VA, Morse GD, Amorosa V, Bhattacharya D, Coughlin K, Wong-Staal F, Glesby MJ; AIDS Clinical Trials Group A5277 Protocol Team. Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study. J Infect Dis. 2014 Mar 1;209(5):658-67. doi: 10.1093/infdis/jit503. Epub 2013 Sep 16. PubMed PMID: 24041792; PubMed Central PMCID: PMC3923538.
3: Faloon PW, Dockendorff C, Yu M, Bennion M, Johnston S, Negri J, Dandapani S, Munoz B, Perez JR, Palmer M, Penman M, Nieland TJF, Krieger M, Schreiber SL. A Small Molecule Inhibitor of Scavenger Receptor BI-mediated Lipid Uptake - Probe 3. 2012 Apr 16 [updated 2013 Mar 14]. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-. Available from http://www.ncbi.nlm.nih.gov/books/NBK143554/ PubMed PMID: 23762924.
4: Faloon PW, Dockendorff C, Germain A, Yu M, Nag PP, Youngsaye W, Bennion M, Lam G, Paterson C, Dandapani S, Munoz B, Perez J, Palmer M, Nieland TJF, Krieger M, Schreiber SL. A Small Molecule Inhibitor of Scavenger Receptor BI-mediated Lipid Uptake—Probe 2. 2011 Dec 15 [updated 2014 Sep 18]. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-. Available from http://www.ncbi.nlm.nih.gov/books/NBK133438/ PubMed PMID: 23658957.
5: Faloon PW, Dockendorff C, Youngsaye W, Yu M, Nag PP, Lewis TA, Bennion M, Paterson C, Lam G, Dandapani S, Munoz B, Perez J, Palmer M, Nieland TJF, Krieger M, Schreiber SL. A Small Molecule Inhibitor of Scavenger Receptor BI-mediated Lipid Uptake—Probe 1. 2011 Dec 15 [updated 2014 Sep 18]. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-. Available from http://www.ncbi.nlm.nih.gov/books/NBK133420/ PubMed PMID: 23658945.
6: Hochreiter J, Lapham J, Wong-Staal F, McKelvy J, Sulkowski M, Glesby MJ, Johnson VA, Morse GD. ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection. Antivir Ther. 2013;18(3):329-36. doi: 10.3851/IMP2354. Epub 2012 Sep 6. PubMed PMID: 22954720.
7: Zhu H, Wong-Staal F, Lee H, Syder A, McKelvy J, Schooley RT, Wyles DL. Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals. J Infect Dis. 2012 Feb 15;205(4):656-62. doi: 10.1093/infdis/jir802. PubMed PMID: 22279172; PubMed Central PMCID: PMC3266130.
8: Syder AJ, Lee H, Zeisel MB, Grove J, Soulier E, Macdonald J, Chow S, Chang J, Baumert TF, McKeating JA, McKelvy J, Wong-Staal F. Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. J Hepatol. 2011 Jan;54(1):48-55. doi: 10.1016/j.jhep.2010.06.024. Epub 2010 Aug 21. PubMed PMID: 20932595.
9: Wong-Staal F, Syder AJ, McKelvy JF. Targeting HCV entry for development of therapeutics. Viruses. 2010 Aug;2(8):1718-33. doi: 10.3390/v2081718. Epub 2010 Aug 18. PubMed PMID: 21994703; PubMed Central PMCID: PMC3185726.
10: Godzik P, Komorowski M, Cielecka-Kuszyk J, Madaliński K. [Inhibitors of hepatitis C virus--therapeutic possibilities]. Przegl Epidemiol. 2010;64(4):479-84. Polish. PubMed PMID: 21473061.
11: Masson D, Koseki M, Ishibashi M, Larson CJ, Miller SG, King BD, Tall AR. Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor. Arterioscler Thromb Vasc Biol. 2009 Dec;29(12):2054-60. doi: 10.1161/ATVBAHA.109.191320. Epub 2009 Oct 8. PubMed PMID: 19815817; PubMed Central PMCID: PMC2783626.
